CLGN
NASDAQ · Biotechnology
Collplant Biotechnologies Lt
$3.79
-0.08 (-2.07%)
Financial Highlights (FY 2026)
Revenue
3.70M
Net Income
-17,932,087
Gross Margin
70.4%
Profit Margin
-484.6%
Rev Growth
+99.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 70.4% | 70.4% | 47.9% | 47.9% |
| Operating Margin | -484.3% | -435.9% | 8.0% | 9.0% |
| Profit Margin | -484.6% | -460.3% | 7.0% | 6.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.70M | 1.86M | 1.91M | 2.00M |
| Gross Profit | 2.60M | 1.31M | 913.8K | 957.4K |
| Operating Income | -17,922,482 | -8,097,913 | 152.5K | 179.9K |
| Net Income | -17,932,087 | -8,102,253 | 134.3K | 123.6K |
| Gross Margin | 70.4% | 70.4% | 47.9% | 47.9% |
| Operating Margin | -484.3% | -435.9% | 8.0% | 9.0% |
| Profit Margin | -484.6% | -460.3% | 7.0% | 6.2% |
| Rev Growth | +99.2% | +99.2% | +10.4% | -4.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 2.78M | 2.74M |
| Total Equity | — | — | 7.05M | 7.15M |
| D/E Ratio | — | — | 0.39 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -16,499,188 | -7,868,983 | 222.2K | 203.5K |
| Free Cash Flow | — | — | 168.1K | 175.1K |